References
- Desjeux P. (2004). Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis, 27:305–318.
- Grevelink SA, Lerner EA. (1996). Leishmaniasis. J Am Acad Dermatol, 34:257–272.
- Croft SL, Coombs GH. (2003). Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol, 19:502–508.
- Garnier T, Croft SL. (2002). Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs, 3:538–544.
- Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR et al. (2002). Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg, 66:147–151.
- Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. (1995). The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother, 35:577–584.
- Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A et al. (1995). A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg, 53:162–166.
- Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. (1995). A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg, 53:648–651.
- Soto J, Fuya P, Herrera R, Berman J. (1998). Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis, 26:56–58.
- Sarveiya V, Templeton JF, Benson HA. (2005). Effect of lipophilic counter-ions on membrane diffusion of benzydamine. Eur J Pharm Sci, 26:39–46.
- Fini A, Fazio G, Gonzalez-Rodriguez M, Cavallari C, Passerini N, Rodriguez L. (1999). Formation of ion-pairs in aqueous solutions of diclofenac salts. Int J Pharm, 187:163–173.
- Megwa SA, Cross SE, Benson HA, Roberts MS. (2000). Ion-pair formation as a strategy to enhance topical delivery of salicylic acid. J Pharm Pharmacol, 52:919–928.
- Abu Hena Mostofa Kamal M, Iimura N, Nabekura T, Kitagawa S. (2006). Enhanced skin permeation of salicylate by ion-pair formation in non-aqueous vehicle and further enhancement by ethanol and l-menthol. Chem Pharm Bull, 54:481–484.
- Lengsfeld CS, Pitera D, Manning M, Randolph TW. (2002). Dissolution and partitioning behavior of hydrophobic ion-paired compounds. Pharm Res, 19:1572–1576.
- Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N et al. (2007). Porcine ear skin: an in vitro model for human skin. Skin Res Technol, 13:19–24.
- Sekkat N, Kalia YN, Guy RH. (2004). Development of an in vitro model for premature neonatal skin: biophysical characterization using transepidermal water loss. J Pharm Sci, 93:2936–2940.
- Barbieri CM, Pilch DS. (2006). Complete thermodynamic characterization of the multiple protonation equilibria of the aminoglycoside antibiotic paromomycin: a calorimetric and natural abundance 15N NMR study. Biophys J, 90:1338–1349.
- Ferreira LS, Ramaldes GA, Nunan EA, Ferreira LA. (2004). In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev Ind Pharm, 30:289–296.
- Lopes LB, Lopes JL, Oliveira DC, Thomazini JA, Garcia MT, Fantini MC et al. (2006). Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm, 63:146–155.
- Weigmann HJ, Ulrich J, Schanzer S, Jacobi U, Schaefer H, Sterry W et al. (2005). Comparison of transepidermal water loss and spectroscopic absorbance to quantify changes of the stratum corneum after tape stripping. Skin Pharmacol Physiol, 18:180–185.
- Carneiro G, Santos DC, Oliveira MC, Fernandes AP, Ferreira LS, Ramaldes GA et al. (2010). Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J Liposome Res, 20:16–23.